

REFERENCE NO.

95

In re application of: Singh, Nikhilesh, et al.
Application No.: 10/763,641
Filing Date: January 22, 2004
Attorney Docket No.: 022205-000110US

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 31/40, A61P 25/06	A1	(11) International Publication Number: WO 00/66115 (43) International Publication Date: 9 November 2000 (09.11.00)
(21) International Application Number: PCT/US99/09414 (22) International Filing Date: 29 April 1999 (29.04.99) (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 09/185,310 (CIP) Filed on 3 November 1998 (03.11.98) (71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB). (71)(72) Applicant and Inventor: CADY, Roger, K. [US/US]; 631 Riverview Road, Ozark, MO 65721 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): GUTTERMAN, Donna, Lee [US/US]; Glaxo Wellcome Inc., Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709 (US). O'QUINN, Stephen, Venson [US/US]; Glaxo Wellcome Inc., Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709 (US).	(74) Agents: LEVY, David, J.; Glaxo Wellcome Inc., Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709-3398 (US) et al. (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>	
(54) Title: DEVICE AND METHOD FOR PROPHYLAXIS OF MIGRAINE		
(57) Abstract <p>The present invention provides a method of preventing the headache phase of migraine in a human comprising administration of a 5HT₁ agonist to said human exhibiting prodrome symptoms of migraine. Suitably, the method comprises administration of migraine headache phase-preventing effective amount of the 5HT₁ agonist. There is disclosed a preemptive prophylaxis migraine method using the following cognitive tests: Simple Reaction Time; Running Memory Continuous Performance Task; Matching to Sample; Mathematical Processing Task; and interprets the results as a percent of baseline indicator of need for prophylaxis. A preemptive prophylaxis migraine device including a microprocessor having a memory, a battery of tests loaded into the memory of the microprocessor and including a Simple Reaction Time, a Running Memory Continuous Performance Task, a Matching to Sample, and a Mathematical Processing Task; means for computing the score on a trial of these tests to establish a baseline and for storing the baseline in the memory; the means for computing being operative for computing the score of a subsequent trial of the tests and comparing the same to the stored baseline; and means for indicating a cognitive change.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

DEVICE AND METHOD FOR PROPHYLAXIS OF MIGRAINE

This application is a continuation-in-part application of and claims priority in the United States to US Serial Number 09/185,310 filed November 3, 1998.

5 The present invention relates to a method of preventing the headache phase of migraine in humans by the administration of 5HT₁ receptor agonists and further relates to a device and method for predicting the onset of a migraine headache.

10 A headache may be one of several different varieties, each of which has its own unique pain characteristics which differ dramatically. The types of headache include tension, sinus, cluster, rebound and migraine. Migraine is a particularly painful headache that recurs from time to time. The pain is quite severe and often the person with migraine must stay in bed. Dietary, emotional and environmental factors may trigger an attack. On average, migraine sufferers experience an attack per month. Attacks last from four to seventy-two hours. Of interest is that the incidence of migraine appears to be on the rise. Because of the severity and incidence of
15 migraine, prescription medicines have been invented to provide relief.

Migraine sufferers sometimes get a warning signal before the onset of the headache phase of a migraine. The warning signals may be classified as aura or prodrome/premonitory symptoms. The International Headache Society (IHS) defines
20 aura as neurological symptoms that usually develop over 5-20 minutes and last less than 60 minutes. Headache may occur directly or after an aura free interval of less than 60 minutes. Aura symptoms commonly include, but are not limited to, visual disturbances and numbness or tingling sensations. Less than 20% of patients have migraine with aura (IHS 1.2). See Headache Classification Committee of the
25 International Society. Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain. *Cephalalgia* (1988); 8: (Suppl 7): 1-96.

The IHS has defined prodrome or premonitory symptoms as non-aura symptoms signalling the onset of a migraine attack. The symptoms typically occur a few hours to 48 hours before the onset of the headache phase of the migraine. Headache phase of migraine as used herein means the point in time when head pain is perceived by the sufferer. Prodrome or premonitory symptoms may occur in migraine with (IHS 1.1) and migraine without aura (IHS 1.2). The IHS prefers the term premonitory symptoms over prodrome due to historical use of prodrome to describe aura. Prodrome symptoms as used herein is synonymous to premonitory symptoms. See Headache Classification Committee of the International Society. Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain. *Cephalalgia* (1988); 8: (Suppl 7): 1-96.

Prodrome or premonitory symptoms may have physical and mental components. The symptoms have been classified by clinical presentation as excitatory and inhibitory symptoms. Excitatory symptoms include, but are not limited to, irritability, euphoria (being 'high'), physical hyperactivity, excessive yawning, excessive sleepiness, increased sensitivity to light and sound, and craving for foods. Inhibitory symptoms include, but are not limited to, depression, mental withdrawal, behaviour sluggishness, feeling tired, poor concentration, muscle weakness, anorexia and fluid retention. See Headache Classification Committee of the International Society. Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain. *Cephalalgia* (1988); 8: (Suppl 7): 1-96 and Anthony M, Rasmussen BK. In: Olesen J, Tfelt-Hansen P, Welch KMA (eds). *The Headaches*. New York: Raven Press, Ltd, 1993: 256-257. Prodrome/premonitory symptoms have been estimated to occur in up to 88% of migraine patients. See *supra*, Rasmussen.

5-HT₁ receptor agonists have been found useful in the treatment of migraine. 5-HT₁ receptors are located, for example, in the dog saphenous vein and the 5HT₁ receptor agonists with which the present invention is concerned contract the dog saphenous vein. Such compounds may therefore be identified by their contractile effect on the

dog isolated saphenous vein strip as described, for example, by Apperley *et al*, Br. J. Pharmacol, 68, 215-224 (1980). Compounds which are selective 5HT₁ receptor agonists have also been found to selectively constrict the carotid arterial bed of the anaesthetised dog.

5 Much work has been done in attempts to identify the subclasses of 5HT₁ receptors which are implicated in migraine. It is currently thought that 5HT_{1B} (formerly 5HT_{1D β}), 5HT_{1D} (formerly 5HT_{1D α}) and 5HT_{1F} receptors are particularly important. Tests in isolated cerebral arteries can be used to determine which of these receptor sub-types mediate the action of 5HT₁ agonist compounds, for example as described in
10 Bouchelet, I. *et al*, Mol. Pharmacol 1996, 50, 219-223.

Some 5HT₁ agonists, including 5HT_{1D} and 5HT_{1F} agonists have also been found to inhibit the trigeminal nerve. This can be assessed by measuring plasma protein extravasation in the dura mater following trigeminal nerve stimulation and administration of labelled albumin; active compounds produce inhibition of dural
15 plasma protein extravasation in this model, which is described in Buzzi. M.G and Moskowitz M.A, Br. J. Pharmacol, 1990 99, 202-206.

A variety of compounds have been identified in the art as 5HT₁ agonists, for example by selective constriction of the dog isolated saphenous vein or constriction of the carotid arterial bed of the anaesthetised dog. These include indole derivatives such as
20 those disclosed *inter alia* in: published British Patent Specification Nos. 2082175, 2081717, 2083463, 2124210, 2150932, 2162522, 2168347, 2168973, 2185020, 2186874, 2191488, 2008646, 2289464, 2289465, 2286185; published US Patent Specification Nos. 5288748, 5317103, 5382592, 5385928, 5387593, 5418236, 5433915, 5451584, 5466688, 5468768, 5519025, 5545644, 5602128, 5618948,
25 5637611, 5837715; published German Patent Specification Nos. 4414113, 4226527; published French Patent Specification Nos. 2699918, 2707294, 2737723; published Japanese Patent Specification Nos. 05320157, 06041071, 07097370, 07109265; published European Patent Specification Nos. 147107, 237678, 242939, 244085,

225726, 254433, 303506, 313397, 354777, 382570, 464558, 506363, 506369, 450238, 451022, 451008, 478954, 438230, 494774, 497512, 501568, 580539, 581538, 586866, 590970, 590971, 603432, 610134, 620222, 620223, 644187, 641787, 645385, 648767, 666258, 668273, 683155, 700905, 703229, 707007, 708102, 712837, 714894, 714896, 729958, 733628, 736525, 747353, 749962, 755932, 768301, 810220; and published International Patent Application Nos. WO92/11013, WO92/11014, WO92/06973, WO93/00086, WO92/13856, WO93/00094, WO91/18897, WO93/00333, WO94/02460, WO94/02477, WO94/03446, WO94/06789, WO94/10171, WO94/11363, WO94/11356, WO94/13620, WO94/14773, WO94/14772, WO94/14771, WO94/14770, WO94/15930, WO94/14779, WO94/18193, WO94/21619, WO94/21611, WO94/21610, WO94/20466, WO94/24127, WO94/29293, WO95/01334, WO95/01965, WO95/05383, WO95/05381, WO95/05366, WO95/06636, WO95/11903, WO95/20588, WO95/21167, WO95/21166, WO95/28933, WO95/32196, WO96/04274, WO96/04269, WO96/06846, WO96/06638, WO96/09288, WO96/11195, WO96/11930, WO96/11923, WO96/11685, WO96/12721, WO96/12713, WO96/16056, WO96/17842, WO96/17831, WO96/16961, WO96/16949, WO96/23789, WO96/23784, WO96/23785, WO96/24596, WO96/29075, WO96/39133, WO97/41802, WO97/03068, WO97/08159, WO97/11695, WO97/13512, WO97/11946, WO97/11945, WO97/17343, WO97/17338, WO97/17337, WO97/18204, WO97/18203, WO97/18202, WO97/18201, WO97/16446, WO97/19073, WO97/38692, WO97/43281, WO97/42189, WO97/45426, WO95/14004, WO98/12183, WO98/14433, WO98/15545. The compounds disclosed in the aforementioned specifications (hereinafter described as "Y compounds") are described as being useful in the treatment of migraine and cluster headache. Some are also claimed to be useful in treating tension-type headache.


Specific examples of 5HT₁ agonist Y compounds include those indole derivatives often called "triptans" such as the compounds with the generic names: sumatriptan, naratriptan, rizatriptan, zolmitriptan, eletriptan, almotriptan and frovatriptan. Other

5

examples of 5HT₁ agonist Y compounds include those commonly known as ALX-0646, LY334370, U109291, IS159 and PNU-142633.

Sumatriptan is marketed *inter alia* in the U.S. as IMITREX[®] (sumatriptan succinate) Tablets, IMITREX[®] (sumatriptan succinate) Injection and IMITREX[®] (sumatriptan) Nasal Spray. In many other countries sumatriptan products are marketed as IMIGRAN[®], rather than IMITREX[®].

IMITREX[®] (sumatriptan succinate) Tablets are indicated for the acute treatment of migraine attacks with or without aura in adults. IMITREX[®] (sumatriptan succinate) Tablets are not approved for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. IMITREX[®] Tablets contain sumatriptan (as its succinate salt), a selective 5HT₁ receptor subtype agonist. Sumatriptan succinate is chemically designated as 3-[2-(dimethylamino)ethyl]-N-methyl-indole-5-methanesulfonamide succinate (1:1), and it has the structure shown in formula (I):




The empirical formula is C₁₄H₂₁N₃O₂S•C₄H₆O₄, representing a molecular weight of 413.5. IMITREX[®] (sumatriptan succinate) Tablets are, for example, disclosed and/or claimed in U.S. 4,816,470, U.S. 5,037,845 and 5,863,559 incorporated by reference herein.

IMITREX[®] (sumatriptan succinate) Injection is indicated for (1) the acute treatment of migraine attacks with or without aura and (2) the acute treatment of cluster

headache episodes. IMITREX® (sumatriptan succinate) Injection is not approved for use in the management of hemiplegic or basilar migraine. The name, structural formula, empirical formula and molecular weight of sumatriptan succinate are as hereinbefore described. IMITREX® (sumatriptan succinate) Injection is, for example,
 5 disclosed and/or claimed in U.S. 4,816,470 and U.S. 5,037,845 incorporated by reference herein.


IMITREX® (sumatriptan) Nasal Spray is indicated for the acute treatment of migraine attacks with or without aura in adults. IMITREX® (sumatriptan) Nasal Spray is not intended for the prophylactic therapy of migraine or for use in the management of
 10 hemiplegic or basilar migraine. IMITREX® (sumatriptan) Nasal Spray contains sumatriptan, a selective 5-hydroxytryptamine₁ receptor subtype agonist. Sumatriptan is chemically designated as 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulfonamide, and it has the structure shown in Formula (II):



The empirical formula is C₁₄H₂₁N₃O₂S, representing a molecular weight of 295.4. Due to the presence of sulphuric acid in the nasal spray formulation, the hemisulphate salt of sumatriptan is formed *in situ*. IMITREX® (sumatriptan) Nasal Spray is, for
 20 example, disclosed and/or claimed in U.S. 4,816,470, U.S. 5,037,845, U.S. 5,705,520 and U.S. 5,554,639 incorporated by reference herein.

Naratriptan is marketed *inter alia* in the United States as AMERGE® (naratriptan hydrochloride) Tablets. In many other countries, the trade mark NARAMIG® is used instead of AMERGE®. AMERGE® Tablets are indicated for the acute treatment of

migraine attacks with or without aura in adults. AMERGE® Tablets are not approved for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. AMERGE® (naratriptan hydrochloride) Tablets contain naratriptan as its hydrochloride salt. Naratriptan hydrochloride is a selective 5HT₁ receptor subtype agonist. It is chemically designated as N-methyl-3-(1-methyl-4-piperidinyl)-1H-indole-5-ethanesulfonamide monohydrochloride, and it has the structure shown in formula (III):



The empirical formula is C₁₇H₂₅N₃O₂S•HCl, representing a molecular weight of 371.93. AMERGE® (naratriptan hydrochloride) Tablets are, for example, disclosed and/or claimed in U.S. 4,997,841 incorporated by reference herein.

Rizatriptan is marketed *inter alia* in the United States as MAXALT® (rizatriptan benzoate) Tablets and MAXALT-MLT™ (rizatriptan benzoate) Orally Disintegrating Tablets. MAXALT® (rizatriptan benzoate) Tablets and MAXALT-MLT™ (rizatriptan benzoate) Orally Disintegrating Tablets are indicated for the acute treatment of migraine attacks with or without aura in adults. MAXALT® (rizatriptan benzoate) Tablets and MAXALT-MLT™ (rizatriptan benzoate) Orally Disintegrating Tablets are not approved for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. MAXALT® (rizatriptan benzoate) Tablets and MAXALT-MLT™ (rizatriptan benzoate) Orally Disintegrating Tablets contain rizatriptan benzoate, a selective 5-HT_{1B/1D} receptor agonist. Rizatriptan benzoate is described chemically as: N,N-dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indole-3-ethanamine monobenzoate. Its empirical formula is C₁₅H₁₉N₅•C₇H₆O₂, representing a

molecular weight of the free base of 269.4. MAXALT® (rizatriptan benzoate) Tablets are, for example, disclosed and/or claimed in U.S. 5,298,520, U.S. 5,602,162, incorporated by reference herein. MAXALT-MLT™ (rizatriptan benzoate) Orally Disintegrating Tablets is, for example, disclosed and/or claimed in U.S. 4,305,502, U.S. 4,371,516, U.S. 4,758,598, U.S. 5,298,520 and U.S. 5,602,162, incorporated by reference herein.

Zolmitriptan is marketed *inter alia* in the United States as ZOMIG™ (zolmitriptan) Tablets. ZOMIG™ (zolmitriptan) Tablets are indicated for the acute treatment of migraine with or without aura in adults. ZOMIG™ (zolmitriptan) Tablets are not approved for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. ZOMIG™ (zolmitriptan) Tablets contain zolmitriptan, which is a selective 5-HT_{1B/1D} receptor agonist. Zolmitriptan is chemically designated as (S)-4-[[3-[2-(Dimethylamino)ethyl]-1 H-indol-5-yl]methyl]-2-oxazolidinone. The empirical formula is C₁₆H₂₁N₃O₂, representing a molecular weight of 287.36. ZOMIG™ (zolmitriptan) Tablets are disclosed and/or claimed in U.S. 5,466,699, incorporated by reference herein.

Other 5HT₁ agonists in development include eletriptan, frovatriptan, almotriptan, ALX-0646, LY334370, U109291, IS159 and PNU-142633.

The above mentioned anti-migraine agents have not been approved for the prevention of migraine. In fact, the current product label for each of these agents states that they are not intended for prophylactic therapy of migraine, e.g., AMERGE® (naratriptan hydrochloride) Tablets. Clinically, these agents are used at the onset of the headache phase of the migraine. (CMAJ 1997;156:1273-1287.) and are commonly reserved for the treatment of severe migraine pain. (Silberstein SD, Lipton RB, Goadsby PJ (eds). *Headache in Clinical Practice*. Oxford UK: Isis Medical Media Ltd, 1998, 74-77.) Thus, it would be desirable to provide an anti-migraine agent useful for the prevention of the headache phase of the migraine. It would be further desirable

to be able to predict the onset of migraine before the head pain actually occurs and thereby permit the prophylactic administration of medicine.

The Automated Neuropsychological Assessment Metrics (ANAM) is a set of standardized batteries of cognitive tests, modified by neuropsychologists in the U.S.

5 Armed Forces for precise measurement of cognitive processing efficiency of military personnel. The tests assess sustained concentration and attention, mental flexibility, spatial processing, cognitive processing efficiency, mood, arousal/fatigue level, and short-term, long-term and working memory. The ANAM is now in the public domain. The most recent version is ANAM V3.11a/96 which includes the following battery of
10 tests:

1. Subject Demographics Form
2. Stanford Sleepiness or Sleep/Fatigue Scale
3. Mood Scale 2
4. Simple and Two-Choice Reaction Time
- 15 5. Sternberg Memory Search Tasks
6. Running Memory Continuous Performance Task
7. Mathematical Processing Task
8. Digit Set Comparison Task
9. Logical Reasoning-Symbolic
- 20 10. Tower of Hanoi (Tower Puzzle)
11. Stroop Color/Word Interference
12. Code Substitution (Letter/Symbol Comparison)
13. Code Substitution (Immediate and Delayed Recall)
14. Spatial Processing Task (Simultaneous)
- 25 15. Matching to Sample
16. Tapping (Left and Right Index Finger)

17. Modified Orientation and Amnesia Test

It would be desirable to be able to use a subset of these tests to predict the onset of migraine before the head pain actually occurs and thereby permit the prophylactic administration of medicine. The present invention is directed to meeting one or more
5 of the above-stated desirable objectives.

The present invention provides a method of preventing the headache phase of migraine in a human comprising administration of a 5HT₁ agonist to said human exhibiting prodrome symptoms of migraine. Suitably, the method comprises administration of a headache phase preventing effective amount of the 5HT₁ agonist.

10 In a second aspect, the invention provides a 5HT₁ agonist for use in the manufacture of a medicament for administration to a human exhibiting prodrome symptoms of migraine in order to prevent the headache phase of migraine.

According to a third aspect, the invention provides a pharmaceutical composition comprising a 5HT₁ agonist as active ingredient for administration to a human
15 exhibiting prodrome symptoms of migraine in order to prevent the headache phase of migraine.

In the second and third aspects, suitably a headache phase-preventing effective amount of a 5HT₁ agonist is administered. In preferred embodiments of the first, second and third aspects, the effective amount is from about 0.25 to 100 mg.

20 The 5HT₁ agonist employed in accordance with the first, second and third embodiment is typically administered orally, parenterally, by inhalation, intranasally or rectally. Parenteral, and oral administration are preferred, with oral administration being particularly preferred.

Suitably, the 5HT₁ agonist administered to said human exhibiting prodrome symptoms
25 of migraine is selected from the group consisting of sumatriptan, naratriptan, rizatriptan, eletriptan, zolmitriptan, frovatriptan, almotriptan, ALX-0646, LY334370, U109291, IS159 and PNU-142633. It is preferably selected from the group consisting

of sumatriptan, naratriptan, rizatriptan, zolmitriptan, eletriptan, frovatriptan and almotriptan. Sumatriptan and naratriptan are particularly preferred, with sumatriptan being especially preferred.

5 When the 5HT₁ agonist is sumatriptan, a headache phase-preventing effective amount is typically from about 2 mg to 100 mg. If the sumatriptan is administered subcutaneously, a headache phase-preventing amount is suitably from about 2 mg to 6 mg. For oral administration, a suitable headache phase-preventing amount is 25 mg to 100 mg. When sumatriptan is administered intranasally, a suitable headache phase-preventing amount is in the range 5 mg to 20 mg. A suitable headache
10 phase-preventing amount of sumatriptan for rectal administration is in the range 12.5 mg to 25 mg.

When the 5HT₁ agonist is naratriptan, a headache phase-preventing effective amount is typically from about 0.25 mg to 2.5 and suitably from 1 mg to 2.5 mg.

15 When the 5HT₁ agonist is rizatriptan, a typical headache phase-preventing effective amount is from about 1 mg to 10 mg, suitably 5 mg to 10 mg.

When the 5HT₁ agonist is zolmitriptan, and a typical headache phase-preventing effective amount is from about 0.5 mg to 5 mg, suitably 1 to 5 mg.

When the 5HT₁ agonist is eletriptan, a typical headache phase-preventing effective amount is from about 5 mg to 80 mg, suitably 20 mg to 80 mg.

20 When the 5HT₁ agonist is frovatriptan, a typical headache phase-preventing effective amount is from about 1 mg to 40 mg, suitably 2.5 mg to 40 mg.

When the 5HT₁ agonist is almotriptan, a headache phase-preventing effective amount is from about 2 mg to 150 mg, suitably 12.5 mg to 25.

25 The present invention further provides a preemptive prophylaxis migraine method using the following cognitive tests: Simple Reaction Time; Running Memory Continuous Performance Task; Matching to Sample; Mathematical Processing Task;

12

and interpreting the results as a percent of baseline indicator of need for prophylaxis. Preferably the tests are administered in the listed sequence. Advantageously the tests are preceded by the Stanford Sleepiness Scale and Mood Scale 2 tests.

5 In accordance with another aspect of the invention there is provided a special purpose microprocessor by which the above tests may be taken by a migraineur. Preferably the device includes two mouse buttons and records performance on the tests. Advantageously the device is a hand-held computer with a fold down screen or a palm-top type computer.

10 In a preferred arrangement there is provided a preemptive prophylaxis migraine device including a microprocessor having a memory, a battery of tests loaded into the memory of the microprocessor and including a Simple Reaction Time, a Running Memory Continuous Performance Task, a Matching to Sample, and a Mathematical Processing Task; means for computing the score on a trial of these tests to establish a baseline and for storing the baseline in the memory; the means for computing being
15 operative for computing the score of a subsequent trial of the tests and comparing the same to the stored baseline; and means for indicating a cognitive change. Other aspects and advantages may be perceived from the following description.

The accompanying drawings illustrate two devices and one method for carrying out the present invention and wherein:

20 Fig. 1 is a plan view of a hand-held computer which is one embodiment of the invention;

Fig. 1A is a plan view of a palm-top type computer which is another embodiment of the invention; and

25 Fig. 2 is a flow chart illustrating the steps and sequence of a method for performing preemptive prophylaxis of migraine.

13

Fig. 1 shows a preemptive prophylaxis of migraine device in the form of a hand-held computer, generally designated 10, and having a key pad 12 and a screen 14 which advantageously is at least four inches (10.16 cm.) square. A hinge 15 is provided so the screen 14 may be conveniently folded down upon the key pad 12 for storage or transporting. When open the computer 10 is conveniently about 5" x 9" (12.7 cm. by 22.86 cm.) in size. The key pad 12 has a built-in set of two mouse buttons 16,18, a start/stop or on/off button 22, an enter key 24, and Mood Scale 2 keys 1, 2 and 3. As used herein the terms "buttons" and "keys" are intended to mean the same thing. The computer 10 contains memory chips (not shown) which have a set of programmed cognitive tests 103-106 (hereafter described) and which record a person's performance time in milliseconds on those tests. The computer program uses the score in milliseconds on the third trial of these cognitive tests as a baseline measurement, which is converted to a stanine score. Subsequent trials are similarly scored and converted to stanine.

Fig. 1A shows a palm-top type computer 10a which, when programmed with the cognitive tests 103-106, performs the same functions as hand-held computer 10. Accordingly, the same functional parts identified in Fig. 1, are identified in Fig. 1A with the same numerals and the letter "a". Further description is deemed unnecessary. It is believed that the largest palm-top computer now available is 7.8 inches (19.81 cm.) long and the screen 14a is not as large as the desired four inches (10.16 cm.) square. However, this deficiency is offset by the savings in using mass produced devices.

Fig 2. shows the sequence of the method. From the seventeen tests of the original ANAM, four subtests were selected and sequenced for measuring cognitive processing efficiency of migraine sufferers, as follows:

1. Simple Reaction Time (SMRT), 103
2. Running Memory Continuous Performance Task (CPT), 104

14

3. Matching to Sample (M2SP), 105
4. Mathematical Processing Task (MATH), 106

Also included are two preliminary measures of alertness and mood that are also part of the ANAM:

- 5 1. Stanford Sleepiness Scale, 101
2. Mood Scale 2, 102

Description of Subtests:

- 10 1. The first step 101 is Stanford Sleepiness Scale which consists of seven statements that describe the present state of alertness or sleepiness and are numbered from one to seven, with one being highly alert and seven being close to sleep. Individuals rate their level of alertness prior to taking the first subtest of the battery. It provides a way to monitor fatigue over the course of repeated measures. Subjective ratings may be correlated with measured performance.
- 15 2. The second step 102 is Mood Scale 2 which consists of a list of thirty-six adjectives that are rated on a three-point scale. Using mouse button 16 participants respond to each adjective by indicating "yes," "moderately," or "no," based on how they feel at the present time. The Mood Scale 2 categories include anger, happiness, fear (anxiety),
20 depression, activity, and fatigue.
- 25 3. The third step 103 is Simple Reaction Time (SMRT) which presents a simple stimulus on the screen (*). In response, the individual presses the mouse button 16 each time the stimulus appears. The Reaction Time measures the speed of the motor response, the peripheral nerve conduction velocity. This represents the "hardware" of the nervous

15

system in terms of input, followed by motor response. Actual cognitive processing time is not involved in this test.

5 4. The fourth step 104 is Running Memory Continuous Performance Test (CPT) which is a continuous letter comparison task. A randomized sequence of upper-case letters, A through Z, is presented one at a time in the center of the computer screen 14. The person presses button 16 if the letter on the screen matches the letter that immediately preceded it; and different button 18 if the letter on the screen is different than the immediately preceding letter. The task lasts approximately five minutes. The CPT was specifically designed to assess components of memory, attention, efficiency and consistency. This task is forced paced, with individuals having only a brief time in which to respond.

15 5. The fifth step 105 is Matching to Sample (M2SP) and consists of a number of trials that begins with a first design being presented in the center of the screen 14 for three seconds, followed by a showing that contains two designs. The person matches one of the two designs with the first design or sample by pressing the appropriate button 16 or 18. The design is a 4 x 4 checkerboard and varies by the number of cells that are shaded from one cell through twelve cells.

20 6. The sixth step 106 is Mathematical Processing (MATH) and involves arithmetic problems presented in the middle of the screen 14. Working from left to right, the person solves the addition and subtraction and decides if the answer is greater or less than the number 5.

25 As indicated, the scores are recorded by the computer 10 and the score on the third trial of these sequenced cognitive tests 103-106 are used as the baseline measurement. Subsequent trials measure cognitive change as compared to baseline. A drop of one in stanine score is an indicator of the onset of migraine and an

indicator of need for prophylaxis. See Fig. 2, 107. This was empirically determined by the following research. The preemptive prophylaxis of migraine method was used to measure cognitive deficiency during a migraine in each of a group of ten migraineurs. The method was used to measure the return of cognitive efficiency after injection of sumatriptan, an anti-migraine medication, in each of the group of ten migraineurs. The method measured cognitive change, compared to the baseline stanine score, that predicted the onset of a migraine.

The above described preemptive prophylaxis of migraine device and method allows a migraine sufferer to take medication to preempt the occurrence of head pain, associated symptoms and accompanying disability.

It will be appreciated that the precise dose of a 5HT₁ agonist administered to prevent the headache phase of migraine may depend on the particular compound used, the age and condition of the patient and the frequency and route of administration and will be at the ultimate discretion of the attendant physician. The compound may be administered in single or divided doses and may be administered one or more times, for example 1 to 3 times per day during exhibition of prodrome symptoms of migraine.

Also, a compound for use according to the invention may be formulated in a conventional manner using one or more pharmaceutically acceptable excipients. Thus, a compound for use according to the invention may for example be formulated for oral, sub-lingual, buccal, parenteral, rectal or intranasal administration or in a form suitable for administration by inhalation or insufflation (either through the mouth or nose).

For oral administration the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (eg pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (eg lactose, microcrystalline cellulose or calcium phosphate); lubricants (eg magnesium stearate,

talc or silica); disintegrants (eg potato starch or sodium starch glycollate); or wetting agents (eg sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Preferred tablet formulations of sumatriptan are those described in European Patent No. 0503440.

- 5 Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (eg sorbitol syrup, methyl cellulose or hydrogenated edible
- 10 fats); emulsifying agents (eg lecithin or acacia); non-aqueous vehicles (eg almond oil, oily esters or ethyl alcohol); and preservatives (eg methyl or propyl P-hydroxybenzoates or sorbic acid).

For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

- 15 A compound for use according to the invention may be formulated for parenteral administration by injection, conveniently intravenous, in intramuscular or subcutaneous injection. Formulations for injection may be presented in unit dosage form eg in ampoules or in multi-dose containers, optionally with an added preservative.
- 20 The compositions for parenteral administration may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively, the active ingredient may be in dry form such as a powder, crystalline or freeze-dried solid for constitution with a suitable vehicle, eg sterile pyrogen-free water or isotonic
- 25 saline before use. They may be presented, for example, in sterile ampoules or vials.

A compound for use according to the invention may also be formulated in rectal compositions such as suppositories or retention enemas, eg containing conventional

suppository bases such as cocoa butter or other glyceride. Preferred compositions for rectal administration are those described in European Patent No. 0639072.

Tablets for sub-lingual administration may be formulated in a conventional manner.

5 For intranasal administration a compound for use according to the invention may be used, for example, as a liquid in the form of a spray or drops or as a powder. Suitably the preparation for intranasal administration is delivered in the form of a spray or aerosol from an insufflator or from a pressurised pack or nebuliser with the use of a suitable propellant. Preferably sumatriptan is administered intranasally in the form of its hemisulphate salt in a composition as described in European Patent No. 0490689.

10 For administration by inhalation the compound for use according to the invention is conveniently delivered in the form of an aerosol spray presentation from pressurised packs or a nebuliser, with the use of a suitable propellant, eg dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurised aerosol the dosage unit may
15 be determined by providing a valve to deliver a metered amount. Capsules and cartridges of eg gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of use in the invention and a suitable powder base such as lactose or starch.

20 The invention will now be further illustrated with reference to the following non-limiting examples.

Biological Examples

An open label pilot study was conducted to determine whether oral naratriptan 2.5 mg taken as a single dose during the prodrome could prevent the onset of the headache phase of migraine. Results of the study suggest that administration of 2.5
25 mg naratriptan during prodrome was effective in preventing the onset of the headache phase of migraine.

Twenty patients recruited at 4 study sites were administered oral naratriptan 2.5 mg after onset of prodrome symptoms for a total of 63 prodromes. Sixty percent of the treated prodromes did not progress to headache. The pain severity of headaches that were not prevented were reduced as compared to baseline pain severity of migraine attacks not treated with naratriptan.

An additional 13 patients recruited at a fifth site were also treated. All 13 patients reported headache following each treatment. Upon review, all 13 patients reported onset of headache within 3 hours after administration of naratriptan. Eighty-seven percent of prodromes in this patient group were treated \leq 2 hours before onset of headache. A similar finding was seen at the remaining 4 sites where 15 of the 25 headaches (60%) that were not prevented occurred \leq 2 hours after treatment. This data suggests these patients waited too late to administer naratriptan and may be due to the fact that patients were instructed to record the onset of premonitory symptoms, but were asked to delay treatment until they were sure a migraine headache was imminent. These data were considered independent of the data from the other 4 sites due to the dichotomy of response as compared to the 4 sites in which the response rates ranged from 58% to 66%.


The invention in its broader aspects is not limited to the specific steps shown and described, but departures may be made therefrom within the scope of the accompanying claims without departing from the principles of the invention and without sacrificing its chief advantages.

Claims


1. The use of a 5HT₁ agonist in the manufacture of a medicament for administration to a human exhibiting prodrome symptoms of migraine in order to prevent the headache phase of migraine.
- 5 2. The use according to claim 1 wherein the 5HT₁ agonist is selected from the group consisting of sumatriptan, naratriptan, rizatriptan, zolmitriptan, eletriptan, frovatriptan and almotriptan.
3. The use according to claim 2 wherein the 5HT₁ agonist is sumatriptan.
4. The use according to claim 3 wherein 2 mg to 100 mg of sumatriptan are
10 administered.
5. The use according to claim 2 wherein the 5HT₁ agonist is naratriptan.
6. The use according to claim 5 wherein 0.25 mg to 2.5 mg of naratriptan are administered.
7. The use according to claim 2 wherein the 5HT₁ agonist is rizatriptan.
- 15 8. The use according to claim 7 wherein 5 mg to 10 mg of rizatriptan are administered.
9. The use according to claim 2 wherein the 5HT₁ agonist is zolmitriptan.
10. The use according to claim 9 wherein 1 mg to 5 mg of zolmitriptan are administered.
- 20 11. The use according to claim 2 wherein the 5HT₁ agonist is eletriptan.
12. The use according to claim 11 wherein 20 mg to 80 mg of eletriptan are administered.
13. The use according to claim 2 wherein the 5HT₁ agonist is frovatriptan.

14. The use according to claim 13 wherein 2.5 mg to 40 mg of frovatriptan are administered.
15. The use according to claim 2 wherein the 5HT₁ agonist is almotriptan.
16. The use according to claim 15 wherein 12.5 mg to 25 mg of almotriptan are administered.
- 5
17. A method of preventing the headache phase of migraine in a human comprising administration of a migraine headache phase-preventing amount of a 5HT₁ agonist to a human exhibiting prodrome symptoms of migraine.
18. A pharmaceutical composition comprising a 5HT₁ agonist as active ingredient for administration during the prodrome phase of migraine in order to prevent the headache phase of a migraine.
- 10


1/3
Fig 1



2/3
Fig 1A



3/3

**Fig 2**

INTERNATIONAL SEARCH REPORT

Int. Application No.
PCT/US 99/09414

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/40 A61P25/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 503 440 A (GLAXO GROUP LTD) 16 September 1992 (1992-09-16) cited in the application	1-17
X	page 3, line 42 - line 49	18
Y	EP 0 490 689 A (GLAXO GROUP LTD) 17 June 1992 (1992-06-17) cited in the application	1-17
X	page 2, line 56 - line 57	18
Y	EP 0 303 506 A (GLAXO GROUP LTD) 15 February 1989 (1989-02-15) cited in the application	1-17
X	page 3, line 61 - line 62	18
-/-		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "Z" document member of the same patent family

Date of the actual completion of the international search

24 November 1999

Date of mailing of the international search report

11/01/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 681 epo nl,
Fax: (+31-70) 340-3018

Authorized officer

Seegert, K

INTERNATIONAL SEARCH REPORT

Int. l. Application No.
PCT/US 99/09414

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5 037 845 A (OXFORD ALEXANDER W) 6 August 1991 (1991-08-06) cited in the application	1-17
X	column 2, line 24 - line 27	18
Y	EP 0 497 512 A (MERCK SHARP & DOHME) 5 August 1992 (1992-08-05) cited in the application	1-17
X	claim 8	18
Y	WO 96 11006 A (LILLY CO ELI ;AUDIA JAMES EDMUND (US); BRANCHEK THERESA (US); COHE) 18 April 1996 (1996-04-18)	1-17
X	claim 1	18
E	WO 99 23997 A (CADDY ROGER K) 20 May 1999 (1999-05-20) page 1, line 30 -page 2, line 2; claims	1-18
Y	GILBERT G J: "A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine 'letter;comment!.' NEUROLOGY, (1999 APR 12) 52 (6) 1301-2. , XP002123737	1-17
X	the whole document	18
Y	GILBERT G J: "Sumatriptan prophylaxis for intractable migraine 'letter!.' HEADACHE, (1997 FEB) 37 (2) 113-4. , XP002123738	1-17
X	page 114	18
Y	NEWMAN L C ET AL: "A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine 'see comments!.' NEUROLOGY, (1998 JUL) 51 (1) 307-9. , XP002123739	1-17
X	"Discussion" page 309	18

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/09414

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0503440 A	16-09-1992	AT 165973 T	15-05-1998
		AU 663303 B	05-10-1995
		AU 1326492 A	06-10-1992
		BE 1005086 A	13-04-1993
		CA 2105180 A	09-09-1992
		CH 684242 A	15-08-1994
		CZ 9301849 A	15-06-1994
		CY 2011 A	20-02-1998
		DE 69225421 D	18-06-1998
		DE 69225421 T	15-10-1998
		WO 9215295 A	17-09-1992
		ES 2117015 T	01-08-1998
		FR 2673538 A	11-09-1992
		GB 2254784 A, B	21-10-1992
		HK 19395 A	17-02-1995
		IL 101162 A	20-11-1997
		IT 1271495 B	30-05-1997
		JP 6505020 T	09-06-1994
		MX 9200992 A	01-09-1992
		NL 9200423 A	01-10-1992
		NZ 241873 A	27-06-1994
		OA 9812 A	15-04-1994
		RU 2098093 C	10-12-1997
		SG 169294 G	28-04-1995
		US 5863559 A	26-01-1999
		ZA 9201690 A	02-08-1993
EP 0490689 A	17-06-1992	AP 230 A	27-01-1993
		AT 119881 T	15-04-1995
		AU 650706 B	30-06-1994
		AU 9072091 A	08-07-1992
		BE 1005085 A	13-04-1993
		CA 2098302 A	13-06-1992
		CH 684192 A	29-07-1994
		CN 1063099 A, B	29-07-1992
		CN 1128259 A	07-08-1996
		CZ 9301140 A	16-02-1994
		CY 2005 A	05-12-1997
		DE 69108200 D	20-04-1995
		DE 69108200 T	20-07-1995
		DK 490689 T	22-05-1995
		EG 20219 A	30-11-1997
		WO 9210477 A	25-06-1992
		ES 2069836 T	16-05-1995
		FR 2670487 A	19-06-1992
		GB 2251614 A, B	15-07-1992
		GR 3015430 T	30-06-1995
		HK 82697 A	27-06-1997
		HU 9500422 A	28-09-1995
		IE 62894 B	08-03-1995
		IL 100330 A	18-06-1996
		IT 1252868 B	28-06-1995
		JP 6503560 T	21-04-1994
		MX 9102501 A	01-09-1992
		NL 9102071 A	01-07-1992
		NZ 240942 A	25-03-1994
		PT 99757 A, B	31-12-1992
		US 5554639 A	10-09-1996

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/09414

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0490689 A		US 5705520 A	06-01-1998
EP 0303506 A	15-02-1989	AT 92057 T	15-08-1993
		AU 611469 B	13-06-1991
		AU 2069288 A	16-02-1989
		CA 1310968 A	01-12-1992
		CY 1728 A	06-05-1994
		DE 3882614 A	02-09-1993
		DE 3882614 T	18-11-1993
		DK 455488 A	14-02-1989
		EP 0303507 A	15-02-1989
		ES 2058292 T	01-11-1994
		FI 883744 A, B,	14-02-1989
		GB 2208646 A, B	12-04-1989
		HK 86793 A	27-08-1993
		HU 9500631 A	28-11-1995
		IE 61488 B	02-11-1994
		JP 1131174 A	24-05-1989
		JP 1207288 A	21-08-1989
		JP 1911883 C	09-03-1995
		JP 6033252 B	02-05-1994
		KR 131327 B	17-04-1998
		LU 90160 A	14-01-1998
		LV 5736 A	20-06-1996
		NO 174052 C	09-03-1994
		NZ 225820 A	26-09-1990
		PH 24976 A	26-12-1990
		PT 88255 A, B	30-06-1989
		SG 65393 G	06-08-1993
		US 4997841 A	05-03-1991
		US 5066660 A	19-11-1991
US 5037845 A	06-08-1991	AT 386196 B	11-07-1988
		AT 226685 A	15-12-1987
		AU 573878 B	23-06-1988
		AU 4568985 A	06-02-1986
		BE 903006 A	03-02-1986
		CA 1241004 A	23-08-1988
		CH 666026 A	30-06-1988
		CZ 280530 B	14-02-1996
		CY 1475 A	21-07-1989
		DE 3527648 A	13-02-1986
		DK 351185 A, B,	02-02-1986
		EG 17283 A	30-06-1992
		ES 545810 A	16-10-1986
		ES 552047 A	16-12-1987
		ES 557480 A	16-02-1988
		ES 557481 A	16-02-1988
		ES 557482 A	01-03-1988
		ES 557483 A	16-02-1988
		FI 852969 A, B,	02-02-1986
		FR 2568571 A	07-02-1986
		GB 2162522 A, B	05-02-1986
		GR 851850 A	26-11-1985
		HK 33289 A	28-04-1989
		IE 58122 B	14-07-1993
		IL 75986 A	28-02-1989
		IT 1207325 B	17-05-1989

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/09414

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5037845 A		JP 1894608 C	26-12-1994
		JP 6023197 B	30-03-1994
		JP 61047464 A	07-03-1986
		KE 3858 A	02-06-1989
		LU 86032 A	18-02-1986
		LU 88266 A	03-02-1994
		MX 159672 A	02-08-1989
		MX 14221 A	01-10-1993
		NL 8502171 A,C	03-03-1986
		NO 853046 A	03-02-1986
		NZ 212948 A	29-05-1989
		PH 22850 A	19-01-1989
		PH 24117 A	05-03-1990
		PT 80900 B	30-12-1987
		SE 452460 B	30-11-1987
		SE 8503680 A	02-02-1986
		SK 404191 A	13-09-1995
		SU 1498386 A	30-07-1989
		ZW 12485 A	26-02-1986
EP 0497512 A	05-08-1992	AT 158582 T	15-10-1997
		AU 644939 B	23-12-1993
		AU 1068092 A	06-08-1992
		BG 62024 B	30-12-1998
		CA 2060139 A,C	02-08-1992
		CA 2238140 A	02-08-1992
		CN 1064485 A,B	16-09-1992
		CN 1157821 A	27-08-1997
		CS 9200198 A	12-08-1992
		DE 69222329 D	30-10-1997
		DE 69222329 T	09-04-1998
		DK 497512 T	27-10-1997
		EP 0778275 A	11-06-1997
		ES 2106822 T	16-11-1997
		FI 920442 A	02-08-1992
		FI 973845 A	30-09-1997
		GR 3025026 T	30-01-1998
		HR 930777 A	31-10-1997
		HU 9500500 A	30-10-1995
		IL 100756 A	19-01-1996
		JP 2500280 B	29-05-1996
		JP 5140151 A	08-06-1993
		LU 90338 A	15-03-1999
		LV 12090 A	20-07-1998
		LV 12090 B	20-09-1998
		MX 9200405 A	01-08-1992
		NO 180447 B	13-01-1997
		NZ 241394 A	27-04-1994
		SG 50409 A	20-07-1998
		SI 9210101 A	31-08-1996
		SK 278998 B	06-05-1998
		US 5451588 A	19-09-1995
		US 5602162 A	11-02-1997
		US 5602163 A	11-02-1997
		US 5298520 A	29-03-1994
WO 9611006 A	18-04-1996	US 5698571 A	16-12-1997
		AU 688168 B	05-03-1998

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/09414

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9611006 A		AU 3999695 A	02-05-1996
		CA 2159767 A	06-04-1996
		CZ 9700930 A	17-09-1997
		EP 0705600 A	10-04-1996
		HU 77885 A	28-09-1998
		JP 8208516 A	13-08-1996
		NO 971487 A	02-04-1997
		NZ 296252 A	28-10-1999
WO 9923997 A	20-05-1999	AU 1375699 A	31-05-1999